LONDON and BRENTWOOD, TN--(Marketwire - October 10, 2008) - ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, in accordance with Rule 2.10 of the City Code on Takeovers and Mergers (the "Code"), confirms that as at the close of business on 9 October 2008, the Company has 342,560,165 ordinary shares of 2 pence each in issue and admitted to trading on the London Stock Exchange under the UK ISIN Code GB0007029209.
